Article Text

Download PDFPDF
Response to: Correspondence on “Electrocardiographic findings and prognostic values in patients hospitalised with COVID-19 in the World Heart Federation Global Study” by Marateb et al
  1. Marcelo Martins Pinto-Filho1,
  2. Carla P M Soares1,
  3. Gabriela Miana Paixão1,2,
  4. Antonio Luiz Pinho Ribeiro1,2
  1. 1Telehealth Center, Hospital das Clínicas da Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
  2. 2Internal Medicine, Faculdade de Medicina da Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
  1. Correspondence to Professor Antonio Luiz Pinho Ribeiro, Centro de Telessaúde, Sala 106 Ala Sul, Hospital das Clínicas da Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais 30130-100, Brazil; tom1963br{at}yahoo.com.br

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The Authors' reply We would like to thank the careful reading by Marateb et al1 of our article on the frequency and prognostic value of ECG findings in patients hospitalised with COVID-19,2 a substudy of the World Heart Federation Global COVID-19 Study.3 4 Before answering the specific points raised by the authors, we should clarify some general aspects. Our study does not intend to fill the gaps pointed out by the US Preventive Services Task Force,5 as suggested by the authors. This task force concluded that current evidence is insufficient to define the ‘benefits and harms of screening with resting or exercise ECG to prevent cardiovascular disease (CVD) events in asymptomatic adults at intermediate or high risk of CVD events’.5 We proposed studying the prognostic value of ECG findings in patients hospitalised with COVID-19, that is, hospitalised patients with an acute illness and not asymptomatic, ambulatory patients.

A second general issue is that Marateb and Mañanas considered that we intended to build or validate a clinical prediction model, defined in the TRIPOD statement as a tool ‘that combines multiple predictors by assigning relative weights to each predictor to obtain a risk or probability’ for diagnosis or prognostication, to aid healthcare providers in the decision-making.6 However, we just aimed to ‘prospectively evaluate the prognostic value of major ECG abnormalities in patients hospitalised with COVID-19 in a comprehensive pancontinental study’ …

View Full Text

Footnotes

  • Twitter @MarceloMartinsP, @tomribeiroecg

  • Contributors All authors contributed to further analysis and interpretation of the data, writing the response and reviewing the final text.

  • Funding The WHF COVID-19 Global Cardiovascular Disease Study is funded by WHF and unconditional research grant by Sanofi and Pfizer. The study was conducted independently without any direct involvement of the funders. The funding agencies were not involved in the study design, conduct, analysis or reporting of the results or manuscript preparation. ALPR s supported in part by CNPq (310790/2021-2 and 465518/2014-1), by FAPEMIG (PPM-00428-17 and RED-00081-16) and CAPES (88887.507149/2020-00).

  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles